OmniAb (OABI) Projected to Post Earnings on Friday

Key Points

• OmniAb is expected to report Q3 2026 results after market close on October 30. Analysts forecast a loss of $0.12 per share and revenue of $3.49 million.
• The company beat estimates in its prior quarter, reporting a $0.05-per-share loss versus the expected $0.12 loss and revenue of $13.41 million versus the $4.69 million consensus.
• Analysts maintain a Moderate Buy consensus with an average price target of $11.50, substantially above the stock’s recent $4.78 price; however, OmniAb continues to post negative margins and return on equity.

OmniAb (NASDAQ:OABI - Get Free Report) is expected to post its Q3 2026 results after the market closes on Friday, October 30th. Analysts expect OmniAb to announce earnings of ($0.12) per share and revenue of $3.49 million for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, October 30, 2026 at 8:00 AM ET.

OmniAb (NASDAQ:OABI - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.07. OmniAb had a negative return on equity of 16.59% and a negative net margin of 115.12%. The company had revenue of $13.41 million during the quarter, compared to the consensus estimate of $4.69 million. On average, analysts expect OmniAb to post ($0.35) EPS for the current fiscal year and ($0.22) EPS for the next fiscal year.

OmniAb Stock Down 2.6%

NASDAQ OABI opened at $4.78 on Friday. OmniAb has a fifty-two week low of $1.30 and a fifty-two week high of $5.43. The business has a fifty day moving average of $4.54 and a 200-day moving average of $2.98. The stock has a market cap of $692.05 million, a price-to-earnings ratio of -13.28 and a beta of 0.60.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Weiss Ratings upgraded OmniAb from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, August 20th. HC Wainwright restated a "buy" rating and issued a $11.00 target price on shares of OmniAb in a report on Monday, August 17th. Finally, Leerink Partners upped their target price on shares of OmniAb from $10.00 to $12.00 and gave the company an "outperform" rating in a report on Wednesday, October 7th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $11.50.

OmniAb Company Profile

OmniAb, Inc is a biotechnology company that develops and licenses antibody discovery technologies for use in drug research and development. Its platform is designed to help biopharmaceutical companies generate fully human and species-diverse antibodies that can be evaluated as potential treatments for a range of diseases.

The company's technology portfolio includes genetically engineered animal platforms, such as OmniRat, OmniMouse and OmniChicken, which are used to produce antibody candidates against challenging biological targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.